KR20230041509A - Bacillus infantis HB2 strain and its use for improving skin conditions - Google Patents

Abstract

The present invention relates to a novel Bacillus infantis HB2 strain and a use of the strain for improving skin condition. According to the novel Bacillus infantis HB2 strain according to one aspect of the invention, since the strain has skin regenerating, wound alleviating and skin whitening effects, the strain can be variously applied for the improvement, prevention, or treatment of the skin condition.

Description

Bacillus infantis HB2 strain and its use for improving skin conditions {Bacillus infantis HB2 strain and its use for improving skin conditions}

It relates to novel microorganisms, their lysates, cultures, extracts, and uses for improving skin conditions.

The ecosystem of the skin provides various types of habitats for microorganisms, and a wide range of microorganisms live there. The human host forms a symbiotic relationship with them, and they are known to have many positive effects on the host. The skin constitutes various types of habitats, such as indentations and specialized crevices, and helps a wide range of microorganisms to grow. Basically, the skin forms a physical barrier and helps to defend against potential risk factors and toxic substances from the outside. The skin becomes a point of contact with the external environment and is also a gathering place for various microorganisms (fungi, bacteria, viruses, and small larvae). According to the selection of physical and chemical functions, microorganisms adapt to specialized niches to prepare habitats. In general, the skin is cold, has an acidic nature, and remains dry. Structurally, the epidermis forms the skin barrier, blocks the penetration of microorganisms and toxins, and plays an important role in retaining moisture. The uppermost layer of the epidermis is composed of the stratum corneum. The epidermis has a form called 'brick and mortar structure', and the skin tissue undergoes a continuous self-healing process, and the scales that have passed through the differentiation process are constantly eliminated from the skin tissue.

Probiotics is a collective term for microorganisms that have a beneficial effect on the human body, and refers to microorganisms that benefit the body. Most probiotics known to date are known as lactic acid bacteria. Probiotics have been reported to produce effective effects through various beneficial actions on the human body, but studies on the interaction between skin flora and skin are insufficient.

Accordingly, there is a need to develop dermatophytes that can be usefully used for skin-related conditions.

One aspect is to provide a novel Bacillus infantis strain.

Another aspect is to provide a lysate of the strain, a culture medium, or an extract of the culture medium.

Another aspect is to provide a composition comprising an extract of the strain, its lysate, culture medium, or culture medium.

Another aspect provides a method for preventing, ameliorating, or treating a condition in a subject in need thereof comprising administering to a subject in need thereof an effective amount of a composition described above.

One aspect provides a Bacillus infantis strain.

The strain may be isolated. In this specification, the term “isolated” means something that is artificially separated and available that does not exist in nature. The strain may be isolated from human skin. The strain may be a strain isolated by inoculating human skin cells in TSB (Tryptic Soy Broth) or R2A (Reasoner's 2A) medium and culturing the cultured colony in pure separation culture.

The strain may be a strain belonging to the genus Bacillus ( Bacillus sp. ).

The strain comprises a 16S rRNA having at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 99.5%, or at least about 99.9% sequence identity with SEQ ID NO: 1 it may be The strain may contain the 16S rRNA of SEQ ID NO: 1.

As used herein, the term "sequence identity" refers to the degree of identity of amino acid residues or bases between sequences after aligning both sequences in a specific comparison region so as to match each other as much as possible. Sequence identity can be confirmed according to methods known in the art. The percent of sequence identity can be determined using a known sequence comparison program, examples of which include BLASTN (NCBI), CLC Main Workbench (CLC bio), MegAlign™ (DNASTAR Inc), and the like.

The Bacillus infantis ( Bacillus infantis ) The strain may be a strain deposited with accession number KCCM13021P. The strain deposited with the accession number may be a Bacillus infantis HB2 strain.

The strain may have a skin condition improving effect. For example, the skin condition improvement may be one or more of skin regeneration, wound improvement, and skin whitening.

Another aspect provides a lysate of the strain, a culture medium, or an extract of the culture medium.

Details of the strain are as described above.

In this specification, the term "lysate" may be used interchangeably with "lysate" and may refer to a product obtained by disrupting the cell wall of a strain by chemical or physical force. The homogenate may include the homogenate itself, a concentrate or a lyophilized product thereof.

As used herein, the term "culture medium" may be used interchangeably with "culture supernatant", "conditioned culture medium" or "conditioned medium", and may supply nutrients so that Bacillus infantis strains can grow and survive in vitro. It may mean the entire medium including the strain obtained by culturing the strain in a medium for a certain period of time, its metabolites, extra nutrients, and the like. In addition, the culture solution may mean a culture solution obtained by removing the cells from the cell culture solution obtained by culturing the strain. On the other hand, the liquid from which the cells are removed from the culture solution is also called "supernatant", and the culture solution is left still for a certain period of time to take only the liquid of the upper layer except for the part sunk in the lower layer, remove the cells through filtration, or centrifuge the culture solution to It can be obtained by removing the precipitate and taking only the upper liquid. The "cell" refers to the strain itself of the present invention, and includes the strain itself isolated and selected from a sample or the strain isolated from the culture solution by culturing the strain. The cells can be obtained by centrifuging the culture solution and taking the part that has sunk to the lower layer, or it can be obtained by leaving it for a certain period of time and then removing the upper liquid because it sinks to the lower layer of the culture medium by gravity.

The culture solution may include the culture solution itself obtained by culturing the strain, its concentrate or lyophilisate, or the culture supernatant obtained by removing the strain from the culture solution, its concentrate or lyophilisate.

The culture medium and culture conditions for culturing the Bacillus infantis strain can be appropriately selected or modified by those skilled in the art. For example, the culture medium may be obtained by culturing in a medium (eg, R2A medium or TSB medium) at a temperature above 10 ° C or below 40 ° C for a certain period of time, for example, 4 to 120 hours. .

In one embodiment, the culture supernatant of the strain may be obtained by centrifuging or filtering the strain culture medium to remove the cells.

In another embodiment, the concentrate may be obtained by concentrating the supernatant obtained after centrifuging or filtering the strain culture medium itself or the culture medium.

As used herein, the term "culture broth extract" refers to an extract obtained from the culture medium or a concentrate thereof, and may include an extract, a dilution or concentrate of the extract, a dried product obtained by drying the extract, or a crude or purified product thereof, or a fraction obtained by fractionating the same. can

The strain, a lysate thereof, a culture medium, or an extract of the culture medium may be biologically pure. The strain may be obtained by pure culture.

Another aspect provides the use of a Bacillus infantis strain, a lysate of the strain, a culture medium or an extract of the culture medium. Specifically, it provides a composition comprising a Bacillus infantis strain, a lysate thereof, a culture medium, or an extract of the culture medium.

In the use or composition, the Bacillus infantis strain may be the Bacillus infantis strain according to the above aspect.

The use of the strain may include improving skin conditions, improving skin beauty, and preventing, improving or treating skin diseases.

The skin condition improvement or skin beauty improvement may be one or more of skin regeneration, wound improvement, and skin whitening.

The strain increases migration of fibroblasts; It may be to inhibit or reduce melanin production.

The term “wound” is also called “wound” and means damage to a living body. The damage may be due to external factors such as physical damage, radiation, stimulation by chemicals, proliferation of microorganisms, or internal factors such as stress, but is not limited thereto. The wounds may include all kinds of wounds such as cut wounds, puncture wounds, crack wounds, acne wounds, fissure wounds, thrush wounds, and wound wounds.

The term "skin regeneration" may refer to any action that replenishes a part of the skin when it is lost or damaged or promotes the proliferation and migration of skin cells. As the skin regenerates, wrinkle improvement effects may appear.

The term “wound improvement” can refer to any action that lightens or reduces the extent of scars on the face or body.

The term “wound healing” may refer to a series of biological reactions that repair a wound.

The cause of skin regeneration, wrinkle improvement, wound improvement, or wound healing is not limited, but may be, for example, due to migration or proliferation of skin cells.

The term "skin whitening" may mean not only brightening the skin tone by inhibiting the synthesis of melanin pigment, but also improving skin hyperpigmentation such as spots or freckles caused by ultraviolet rays, hormones, or heredity.

The term “inhibition of melanin production” may mean suppression of new melanin production in cells or the like.

The term “inhibition of melanin secretion” may mean suppression of secretion of melanin from cells or the like.

The term "reducing melanin" may mean reducing the content of melanin existing in cells or the like.

The skin disease may be a skin wound, skin scar, or hypermelanin hyperpigmentation disease.

The term "melanin hyperpigmentation" is a broad concept that includes all melanin hyperplasia caused by various causes, and means that certain parts of the skin, nails, or toenails become darker than other parts due to excessive increase in melanin pigment. .

The melanin hyperpigmentation disease is freckles (freckle); melasma; chloasma; liver spots; nevus; solar lentigo; melanosis; peutz-jegher's syndrome; gestational brown spots (chloasma gravidarum); hyperpigmentation after drug use; And it may be any one selected from postinflammatory hyperpigmentation (postinflammatory hyperpigmentation), but is not limited thereto.

The term "prevention" includes inhibiting the development of a disease. The term "treatment" includes inhibition of the development of, alleviation of, or elimination of a disease. The term "improvement" can mean any action that at least reduces a parameter associated with alleviation or treatment of a condition, eg, the severity of a symptom.

The composition according to one aspect includes the Bacillus infantis strain, a lysate thereof, a culture medium, or an extract of the culture medium, thereby increasing the migration of fibroblasts to exhibit skin regeneration, wound healing, wound healing, or wrinkle improvement effects.

The composition according to one aspect includes the Bacillus infantis strain, a lysate thereof, a culture medium, or an extract of the culture medium, thereby inhibiting or reducing melanin production, resulting in skin whitening effect, or prevention of skin diseases such as melanin hyperpigmentation disease, may have an ameliorative or therapeutic effect.

In another embodiment, the strain may exhibit a synergistic effect when used together with other strains having a skin condition improving effect, for example, strains belonging to the genus Bacillus. Strains belonging to the Bacillus genus include, for example, Bacillus subtilis , Bacillus coagulans , Bacillus amyloliquefaciens , Bacillus licheniformis , Bacillus atrophaeus , Bacillus thermolactis , Bacillus thermoamylovorans , Bacillus aryabhattai , Bacillus aerius , Bacillus circulans , Bacillus flexus , Bacillus kokeshii formisashi , Bacillus jejuensis , Bacillus cereus , Bacillus megaterium , Bacillus thermocopriae , Bacillus velezensis , Bacillus siamensis , Bacillus altitudinis , and the like.

The composition is 0.001% to 80% by weight, for example, 0.01% to 60% by weight, 0.01% to 40% by weight, 0.01% to 30% by weight, 0.01% to 20% by weight, based on the total weight of the composition. %, 0.01% to 10%, 0.01% to 5%, 0.05% to 60%, 0.05% to 40%, 0.05% to 30%, 0.05% to 20%, 0.05% to 10% by weight, 0.05% to 5% by weight, 0.1% to 60% by weight, 0.1% to 40% by weight, 0.1% to 30% by weight, 0.1% to 20% by weight, 0.1% by weight % to 10% by weight, or 0.1% to 5% by weight of the strain, a lysate thereof, a culture medium, or an extract of the culture medium. At this time, if the content of the strain, its lysate, culture medium, or extract of its culture medium is less than the above range, the skin condition improvement effect, for example, skin regeneration, wound improvement, or skin whitening effect may not be sufficiently exhibited.

As used herein, the term "included as an active ingredient" means that the strain of the present specification, its lysate, culture medium or extract of the culture medium is added to the extent that the above-mentioned effects can be exhibited, and for drug delivery and stabilization, etc. It means that it is formulated in various forms by adding various components as subcomponents.

The composition may be in a liquid or dry state. In one embodiment, the composition may be in the form of a dry powder.

A drying method for preparing the composition in a dry state may use a method commonly used in the art, and is not particularly limited. Non-limiting examples of the drying method include an air drying method, a natural drying method, a spray drying method, a freeze drying method, and the like. These methods may be used alone or at least two methods may be used together.

The composition may contain an additive in an effective amount sufficient to reduce deterioration of the strain, its lysate, culture medium or extract of the culture broth. The additive may be, for example, a binder, but is not limited thereto.

The composition may further include a cosmetically, pharmaceutically or food-acceptable carrier. The composition may be formulated with a carrier and provided as cosmetics, drugs, food additives, and the like.

The composition may be a cosmetic composition.

The cosmetic composition may further include ingredients commonly used in cosmetic compositions, functional additives, etc. in addition to the active ingredients disclosed herein, such as antioxidants, stabilizers, solubilizers, surfactants, dispersants, emulsifiers, and preservatives. , conventional adjuvants such as vitamins, pigments, flavors, and the like, and carriers.

The cosmetic composition is not particularly limited to a specific formulation, and the formulation may be appropriately selected according to the purpose. The cosmetic composition may have, for example, a solubilizing formulation, an emulsifying formulation, or a dispersion formulation. The cosmetic composition may have, for example, a softening lotion, a nutrient lotion, a massage cream, a nutrient cream, an essence, a pack, a gel, an ampoule, or a skin-adhesive cosmetic formulation.

The composition may be a composition for external application for skin.

In the present specification, the external skin preparation may be a cream, gel, ointment, skin emulsifier, skin suspension, transdermal delivery patch, drug-containing bandage, lotion, or a combination thereof. The external skin preparation is a component usually used in external preparations for skin such as cosmetics or pharmaceuticals, for example, water-based components, oil-based components, powder components, alcohols, moisturizers, thickeners, ultraviolet absorbers, whitening agents, preservatives, antioxidants, surfactants, and fragrances. , colorants, various skin nutrients, or combinations thereof and may be suitably blended as needed. The skin external preparation, metal sequestering agents such as disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, gluconic acid; drugs such as caffeine, tannin, bellapamil, licorice extract, glabridin, hot water extract of calin fruit, various herbal medicines, tocopherol acetate, glycylitnic acid, tranexamic acid and its derivatives or salts; Vitamin C, magnesium ascorbyl phosphate, ascorbic acid glucoside, arbutin, kojic acid; Sugars, such as glucose, fructose, and trehalose, etc. can also be mix|blended suitably.

The composition may be a pharmaceutical composition.

The pharmaceutical composition may additionally include a pharmaceutically acceptable diluent or carrier. The diluent may be lactose, corn starch, soybean oil, microcrystalline cellulose, mannitol, or a combination thereof. The carrier may be an excipient, a disintegrant, a binder, a lubricant, or a combination thereof. The excipient may be microcrystalline cellulose, lactose, low-substituted hydroxycellulose, or a combination thereof. The disintegrant may be calcium carboxymethylcellulose, sodium starch glycolate, calcium monohydrogen phosphate, or a combination thereof. The binder may be polyvinylpyrrolidone, low-substituted hydroxypropylcellulose, hydroxypropylcellulose, or a combination thereof. The lubricant may be magnesium stearate, silicon dioxide, talc, or a combination thereof.

The pharmaceutical composition may be formulated for oral or parenteral administration. Oral dosage forms may be granules, powders, liquids, tablets, capsules, dry syrups, and the like. Parenteral dosage forms may be injections, ointments, and the like.

The composition may be a health functional food composition. In this case, it may be formulated in the form of a conventional health functional food known in the art.

The health functional food composition may be used alone, or in combination with other foods or food ingredients, and may be appropriately used according to conventional methods. The mixing amount of the active ingredient may be appropriately determined depending on the purpose of use (prevention, health or therapeutic treatment). There is no particular limitation on the type of health functional food. Among the types of health functional foods, beverage compositions may contain various flavoring agents or natural carbohydrates as additional components, like conventional beverages. The natural carbohydrates include monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; and polysaccharides such as dextrins and cyclodextrins; It is a sugar alcohol, such as xylitol, sorbitol, and erythritol. As the sweetener, natural sweeteners such as thaumatin and stevia extract, or synthetic sweeteners such as saccharin and aspartame may be used. The food composition is also used in nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohols, carbonated beverages carbonation agent, or a combination thereof. The food composition may also contain natural fruit juice, fruit juice beverages, fruit flesh for preparing vegetable beverages, or a combination thereof.

Another aspect provides a method for preventing, ameliorating, or treating a condition in a subject in need thereof comprising administering to a subject in need thereof an effective amount of a composition described above.

The condition of the subject may be a skin-related condition, for example, a skin wound or a condition related to melanin hyperpigmentation.

The terms "administering," "introducing," and "implanting" are used interchangeably herein, and according to one embodiment, a subject by a method or route that results in at least partial localization of a composition to a desired site. It can mean the placement of a composition according to one embodiment into.

Administration may be administered by a method known in the art. Administration may be administered directly to a subject by any means, for example, by routes such as intravenous, intramuscular, oral, transdermal, mucosal, intranasal, intratracheal or subcutaneous administration. can The administration may be administered systemically or locally. The administration may include application to the skin.

The subject may be a mammal, such as a human, cow, horse, pig, dog, sheep, goat, or cat. The subject may be a subject in need of skin improvement, for example, a subject in need of skin regeneration, wound improvement, or skin whitening effect.

The administration is 0.1 mg to 1,000 mg per day of the composition according to one embodiment, for example, 0.1 mg to 500 mg, 0.1 mg to 100 mg, 0.1 mg to 50 mg, 0.1 mg to 25 mg, 1 mg to 1,000 mg, 1 mg to 500 mg, 1 mg to 100 mg, 1 mg to 50 mg, 1 mg to 25 mg, 5 mg to 1,000 mg, 5 mg to 500 mg, 5 mg to 100 mg, 5 mg to 50 mg , 5 mg to 25 mg, 10 mg to 1,000 mg, 10 mg to 500 mg, 10 mg to 100 mg, 10 mg to 50 mg, or 10 mg to 25 mg may be administered. However, the dosage may be prescribed in various ways depending on factors such as formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate and reaction sensitivity, and those skilled in the art can Dosage can be appropriately adjusted in consideration of these factors. The number of administrations can be once a day or two or more times within the range of clinically acceptable side effects, and administration can be performed at one or two or more sites, daily or at intervals of 2 to 5 days. The number of administration days may be administered from 1 day to 30 days per treatment. If necessary, the same treatment can be repeated after a titration period. For non-human animals, the same dosage per kg as for humans is used, or the above dosage is converted by the volume ratio (eg, average value) of the organ (heart, etc.) between the target animal and the human. A single dose can be administered.

According to the novel Bacillus infantis strain according to one aspect, since it has skin regeneration, wound improvement, or skin whitening effects, it can be variously applied for improvement, prevention, or treatment of skin conditions.

1 is a graph showing relative wound density (%) over time and a photograph confirming cell saturation in a culture dish. HB2: HB2 strain culture solution addition group; TSB (medium): medium added group; and None: no additives.
Figure 2 is a photograph and a graph showing the effect of each test group on melanin production inhibition. None: no additives; Veh.: Vehicle (100 nM α-MSH) alone added group; TSB: medium added group; HB2: HB2 strain culture solution addition group; and Arbutin: arbutin-added group as a positive control group.

Hereinafter, the present invention will be described in more detail through examples. However, these examples are intended to illustrate the present invention by way of example, and the scope of the present invention is not limited to these examples.

Example 1. Isolation and identification of strains

Bacillus infantis strains were isolated and identified from the skin of healthy women.

Specifically, the cheeks, tip of the nose, and borders of the nostrils of healthy women were swabbed 2 to 3 times with sterile cotton swabs soaked in PBS (phosphate buffer saline). A cotton swab was placed in a tube containing PBS and vortexed for 10 seconds. 10-fold, 100-fold, and 1,000-fold dilutions of the sample were prepared, and 100 μL of each was added to 0.1X TSB (Tryptic Soy Broth) and 0.5X R2A (Reasoner's 2A) agar medium and spread with a spreader, and the plate was 30 ° C or 37 C. and colonies were isolated. The cultured colony was subjected to 16S rRNA gene sequence identification. Primers used at this time were designed to amplify in response to bacteria only (27F, 5'-AGAGTTTGATCCTGGCTCAG-3' (SEQ ID NO: 2); 1492R, 5'-GGTTACCTTGTTACGACTT-3 (SEQ ID NO: 3)). PCR amplification was carried out in 30 cycles of 95 ° C for 1 minute, 55 ° C for 1 minute, and 75 ° C for 1 minute and 30 seconds, and finally treated at 72 ° C for 8 minutes and stored at 4 ° C. After the PCR reaction, the DNA sequences of the isolated and cultured microorganisms were determined using ABI-3730XL (ABI, USA). When the nucleotide sequence of the determined 16S rRNA region was compared with other strains registered by the BLAST program provided on the website of the National Center for Biotechnology Information (NCBI), a novel microorganism Bacillus infantis with 99.78% homology ( Bacillus infantis ) strain (hereinafter referred to as "HB2") was selected.

The selected HB2 strain was deposited with the Korea Microorganism Conservation Center (KCCM) on July 20, 2021 and was given accession number KCCM13021P. HB2 strain has a 16S rRNA sequence of SEQ ID NO: 1 (complementary DNA).

Example 2. Preparation of HB2 strain culture solution

After culturing the HB2 strain of Example 1 in TSB medium, the cells were removed through centrifugation, and the HB2 strain culture solution was prepared through supernatant recovery and filtration.

Experimental Example 1. Skin regeneration and wound healing effect - check fibroblast migration increasing ability

In order to analyze the effect of the HB2 strain culture medium on skin regeneration, a fibroblast migration experiment was performed.

Specifically, the human dermal fibroblast cell line (Human dermal fibroblast, Hs68) was dispensed in 3x10 ⁵ in a 6-well plate, and then cultured for 24 hours in an incubator at 37°C, 5% CO ₂ conditions to reach 100% confluent. made the state Thereafter, the center of the cultured cell was scratched using a cell scrapper, and then replaced with a medium containing and without the HB2 strain culture medium (1% (w/w)) of Example 2, and then It was further incubated for 24 hours. After 24 hours, the degree of recovery of the wounds randomly made on the cells was photographed with a fluorescence microscope, and the results are shown in FIG. 1.

1 is a graph showing relative wound density (%) over time and a photograph confirming cell saturation in a culture dish.

As shown in Figure 1, it was confirmed that the HB2 strain culture significantly increased the migration of fibroblasts to the damaged area.

Therefore, it was found that the Bacillus infantis HB2 strain has skin regeneration and wound healing effects.

Experimental Example 2. Whitening effect - confirmation of melanin production inhibition

In order to analyze the skin whitening activity of the HB2 strain culture medium, the ability to inhibit melanin production was measured.

Specifically, mouse pigment B16-F10 (Murine Melanoma) cells (ATCC) were suspended in 2 ml of DMEM medium (Dulbecco's modified Eagle's Medium, Gibco 1210-0038) containing 10% FBS, and 1x10 ⁵ cells/well were 6 - After inoculation into the well plate, the cells were cultured for 24 hours in a 37°C, 5% CO ₂ incubator until 40-50% of the cells adhered to the bottom of the well. Thereafter, α-MSH (α-melanocyte stimulating hormone) was treated at a concentration of 100 nM to induce melanin production. Next, the HB2 strain culture medium (1% (w / w)) of Example 2 was treated and further cultured for 3 days. Thereafter, the culture medium was collected and centrifuged at 1,000 rpm for 10 minutes to obtain a supernatant. The absorbance of the supernatant was measured three times at 490 nm with a microplate reader (Victor 3) to evaluate the ability to inhibit melanin secretion. Melanin content was evaluated by the following formula, and the results are shown in FIG. 2 . As a positive control group, 100 ppm of arbutin (Sigma Aldrich) was used.

[formula]

Melanin contents (%) = (average absorbance of each sample treatment group) / (average absorbance of α-MSH treatment group) x 100 (%)

Figure 2 is a photograph and a graph showing the effect of each test group on melanin production inhibition.

As shown in Figure 2, it was confirmed that the HB2 strain significantly reduced melanin increased by α-MSH compared to the untreated control group.

Accordingly, it was found that the Bacillus infantis HB2 strain has a skin whitening effect.

Taken together, the Bacillus infantis HB2 strain increases fibroblast migration; It was confirmed that the melanin production was inhibited or reduced. Accordingly, it was found that the Bacillus infantis HB2 strain has skin regeneration, wound improvement (healing) and skin whitening effects.

The above description is merely an example of the technical idea of the present invention, and various modifications and variations can be made to those skilled in the art without departing from the essential characteristics of the present invention.

Korea Microbial Conservation Center (Overseas) KCCM13021P 20210720

SEQUENCE LISTING <110> Cosmax, INC. <120> Bacillus infantis HB2 strain and its use for improving skin conditions <130> PN140320EN <160> 3 <170> PatentIn version 3.2 <210> 1 <211> 1395 <212> DNA <213> Bacillus infantis <400> 1 taccccaccg acttcgggtg ttacaaactc tcgtggtgtg acgggcggtg tgtacaaggc 60 ccgggaacgt attcaccgcg gcatgctgat ccgcgattac tagcgattcc agcttcatgc 120 aggcgagttg cagcctgcaa tccgaactga gaatggtttt atgggattcg cttaacctcg 180 cggtcttgca gccctttgta ccatccattg tagcacgtgt gtagcccagg tcataagggg 240 catgatgatt tgacgtcatc cccaccttcc tccggtttgt caccggcagt caccttagag 300 tgcccaactg aatgctggca actaagatca agggttgcgc tcgttgcggg acttaaccca 360 acatctcacg acacgagctg acgacaacca tgcaccacct gtcatcctgt cccccgaagg 420 ggaacgccct atctctaggg ttgtcaggag atgtcaagac ctggtaaggt tcttcgcgtt 480 gcttcgaatt aaaccacatg ctccaccgct tgtgcgggcc cccgtcaatt cctttgagtt 540 tcagccttgc ggccgtactc cccaggcgga gtgcttaatg cgtttgctgc agcactaaag 600 ggcggaaacc ctctaacact tagcactcat cgtttacggc gtggactacc agggtatcta 660 atcctgtttg ctccccacgc tttcgcgcct cagcgtcagt tacagaccag aaagtcgcct 720 tcgccactgg tgttcctcca catctctacg catttcaccg ctacacgtgg aattccactt 780 tcctcttctg cactcaagtc ccccagtttc caatgaccct ccacggttga gccgtgggct 840 ttcacatcag acttaagaga ccgcctgcgc gcgctttacg cccaataatt ccggacaacg 900 cttgccacct acgtattacc gcggctgctg gcacgtagtt agccgtggct ttctggtcag 960 gtaccgtcaa ggtgccggca gttactccgg cacttgttct tccctgacaa cagagtttta 1020 cgatccgaaa accttcatca ctcacgcggc gttgctccgt cagactttcg tccattgcgg 1080 aagattccct actgctgcct cccgtaggag tctgggccgt gtctcagtcc cagtgtggcc 1140 gatcaccctc tcaggtcggc tacgcatcgt tgccttggtg agccgttacc tcaccaacta 1200 gctaatgcgc cgcgggccca tctgtaagtg atagccgaaa ccatctttca gcatarcctc 1260 atgagaggyt rtgcattatc cggtattagc tccggtttcc cgaagttatc ccagtcttac 1320 aggcaggttg cccacgtgtt actcacccgt ccgccgctga cttcaggggag caagctccca 1380 tccgtccgct cgact 1395 <210> 2 <211> 20 <212> DNA <213> artificial <220> <223> 27F primer <400> 2 agagtttgat cctggctcag 20 <210> 3 <211> 19 <212> DNA <213> artificial <220> <223> 1492R primer <400> 3 ggttaccttg ttacgactt 19

Claims (10)

Deposited under accession number KCCM13021P, Bacillus infantis HB2 strain. The strain according to claim 1, comprising a 16S rRNA having a sequence identity of 98% or more with SEQ ID NO: 1. A cosmetic composition comprising the strain of claim 1, a lysate thereof, a culture medium, or an extract of the culture medium. The cosmetic composition according to claim 3, which is for improving skin conditions. The cosmetic composition according to claim 4, wherein the skin condition improvement is at least one of skin regeneration, wound improvement, and skin whitening. The method of claim 3, which increases the migration of fibroblasts; A cosmetic composition that inhibits or reduces melanin production. A composition for external application for skin for skin regeneration or wound improvement comprising the strain of claim 1, a lysate thereof, a culture medium, or an extract of the culture medium. A composition for external application for skin for skin whitening comprising the strain of claim 1, a lysate thereof, a culture medium, or an extract of the culture medium. A health functional food composition for skin regeneration or wound improvement comprising the strain of claim 1, a lysate thereof, a culture medium, or an extract of the culture medium. A health functional food composition for skin whitening comprising the strain of claim 1, a lysate thereof, a culture medium, or an extract of the culture medium.

Images